Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 7/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6188999 | 0.91 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6189169 | 0.84 | CHRNB2 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL7688755 | 0.84 | CHRNB2 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL7685725 | 0.82 | CHRNB2 (0.59) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6186900 | 0.81 | CHRNB4 (0.65) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6188593 | 0.81 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6188155 | 0.81 | CHRNB2 (0.58) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL7681243 | 0.78 | CHRNA4 (0.66) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6189360 | 0.78 | CHRNB2 (0.58) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6191054 | 0.78 | CHRNB2 (0.54) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274710-B1 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH AS (DK) | 2005-02-23 | — | — | EP | claimed |
| US-6815438-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | NEUROSEARCH A/S (DK) | 2004-11-09 | — | — | US | claimed |
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | NEUROSEARCH A/S (DK) | 2003-01-02 | — | — | US | claimed |
| EP-1274710-B1 | NOVEL HETEROARYL-DIAZABICYCLOALKANES | NEUROSEARCH AS (DK) | 2005-02-23 | — | — | EP | disclosed |
| US-6815438-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | NEUROSEARCH A/S (DK) | 2004-11-09 | — | — | US | disclosed |
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | NEUROSEARCH A/S (DK) | 2003-01-02 | — | — | US | disclosed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004153-A1 | Novel heteroaryl-diazabicycloalkanes | CHRNA2, CHRNA5, CHRNA6 | CHRNB4 11/4885CHRNA3 5/4885CHRNB2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.